Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions surrounding the publication show a mix of excitement and inquiry about THCV’s effects on glucose levels in patients with type 2 diabetes. For example, users reference the double-blind, randomized controlled trial to stress the credibility of THCV's impact, with phrases like 'can THCV replace a diabetic's insulin?' suggesting a real engagement with the implications of the research. The tone is enthusiastic, with users contemplating THCV's potential as a game-changing solution for diabetes, reflecting a strong interest and perceived significance of the study.
Most discussions reflect a supportive stance toward the findings of the publication, highlighting the benefits of THCV.
Participants show a strong curiosity, often asking questions and sharing insights about the implications of the study.
Many posts delve into the specifics of THCV’s effects and potential as a treatment, indicating a high level of engagement with the research.
Users express belief that the study's findings could significantly affect diabetes management practices.
COVID is an opportunistic accelerant of metabolic disease. ~90% of patients are comorbid with diabetes, hypertension, cancer, COPD. Cannabinoids are metabolic regulators. RCT on CBD and THCV for TypeII diabetes. https://t.co/CItWUU0GMG
In a double-blind, randomized controlled trial in type 2 diabetics, THCV significantly decreased fasting plasma glucose and improved pancreatic β-cell function and apolipoprotein A (a marker for CVD disease) compared to placebo. https://t.co/2GXdYZjvXM https://t.co/f4rXSabuYO https://t.co/BpAhe54pwR
Can THCV replace a diabetic's insulin? In a double-blind, randomized controlled trial, THCV significantly decreased fasting plasma glucose and improved pancreatic β-cell function (increased insulin output) compared to placebo. https://t.co/2GXdYZ1V6e @drcaplan @joerogan https://t.co/eaZRXl6MtA
THCV is one of the most interesting minor cannabinoids associated with #cannabis. One thing I find particularly interesting is that there's evidence it can cause physiological effects (e.g. lower plasma glucose) when consumed at a low dose (5-10 mg). https://t.co/tZcGANLYLI
未だ納得いかない #THCV https://t.co/PB9OQ8ukfB
Until then, here’s a scientific study from @ADA_Pubs with some of the research done on THCV - https://t.co/v2HcQaGLax
In this video, Carri discusses THCV, a new cannabinoid of interest. While CBD has gained attention for its anti-inflammatory and neuroprotective effects in sports, THCV's role is emerging, warranting further…
Should athletes use CBD? This video discusses CBD's potential anti-inflammatory and neuroprotective properties, which could be beneficial for sports performance. Consult a healthcare professional before use, and ensure…
This video discusses how THCV can help manage diabetes. CBD offers potential benefits such as anti-inflammatory and neuroprotective effects, but further research is needed. Remember to consult your healthcare…
THCV, a cannabinoid of interest, may aid in weight loss. This video examines its potential effects alongside CBD's benefits in sports performance, such as anti-inflammatory and neuroprotective properties. Tune in for…
In this video, Carri discusses the importance of timing your munchies for effective weight management. CBD's potential benefits, including its anti-inflammatory and neuroprotective effects, are highlighted. However…
In this video, Carri explains which cannabinoid can help you lose weight, focusing on the potential benefits of CBD. With research highlighting CBD's anti-inflammatory and neuroprotective effects, it presents a…
@MJTruthUltra THCV tetrahydrocannabivarin I work with patients whose A1C is 6+ even on medication; when THCV is added, glucose levels drop to WNL THCV is extracted from hemp & regulates glucose & lipid metabolism naturally Why don't physicians know this?
RT @Greenthumb_one: Resharing from @drcaplan Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Paramete…
RT @drmikehart: Can THCV replace a diabetic's insulin? In a double-blind, randomized controlled trial, THCV significantly decreased fast…
RT @drmikehart: Can THCV replace a diabetic's insulin? In a double-blind, randomized controlled trial, THCV significantly decreased fast…
RT @drmikehart: Can THCV replace a diabetic's insulin? In a double-blind, randomized controlled trial, THCV significantly decreased fast…
RT @Greenthumb_one: Resharing from @drcaplan Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Paramete…
https://t.co/6158eJWgLI
Resharing from @drcaplan Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study https://t.co/00WDeZrNBq
RT @drmikehart: Can THCV replace a diabetic's insulin? In a double-blind, randomized controlled trial, THCV significantly decreased fast…
RT @drmikehart: Can THCV replace a diabetic's insulin? In a double-blind, randomized controlled trial, THCV significantly decreased fast…
RT @drmikehart: Can THCV replace a diabetic's insulin? In a double-blind, randomized controlled trial, THCV significantly decreased fast…
Can THCV replace a diabetic's insulin? In a double-blind, randomized controlled trial, THCV significantly decreased fasting plasma glucose and improved pancreatic β-cell function (increased insulin output) compared to placebo. https://t.co/2GXdYZ1V6e @drcaplan @joerogan https://t.co/eaZRXl6MtA
未だ納得いかない #THCV https://t.co/PB9OQ8ukfB
エビデンスはこちら https://t.co/COR1IIIOYq
RT @Organigram_Inc: Until then, here’s a scientific study from @ADA_Pubs with some of the research done on THCV - https://t.co/v2HcQaGLax
@mfcannabis AFAIK any blue dream strain is heavier in THC-V, also Shred has a cartridge. Besides that it is being studied for use with diabetic populations https://t.co/zoaVx2LyyV
RT @Organigram_Inc: Until then, here’s a scientific study from @ADA_Pubs with some of the research done on THCV - https://t.co/v2HcQaGLax
Until then, here’s a scientific study from @ADA_Pubs with some of the research done on THCV - https://t.co/v2HcQaGLax
@WhatsMyPot @askcannaqueen @Modanya Here's an article to check out: https://t.co/ekBDnTwrqm we're not endorsing it or anything, but some cool info here. Can share some THCV levels of our cultivar "Get Sh*t Done" if you want.
Dati degli studi clinici hanno precedentemente dimostrato che la somministrazione del cannabinoide #THCV (tetraidrocannabivarina) riduce i livelli di glucosio a digiuno nei diabetici di tipo 2. More info: .https://t.co/hIHX2ujb7R .https://t.co/grwc6tyWMu .https://t.co/nAdswEdx60
@EvertRauwendaal @AlexWodak I’ll take plant based THCV preparation for $100 Alex https://t.co/3y9trTxC8s https://t.co/wo4lRXzcCU
...and diabetes. "Compared with placebo, THCV significantly decreased fasting plasma glucose" https://t.co/7XIptsodKE (7/10)
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Typ… https://t.co/8kOxrjSylo
RT @drmikehart: In a double-blind, randomized controlled trial in type 2 diabetics, THCV significantly decreased fasting plasma glucose and…
RT @drmikehart: In a double-blind, randomized controlled trial in type 2 diabetics, THCV significantly decreased fasting plasma glucose and…
RT @drmikehart: In a double-blind, randomized controlled trial in type 2 diabetics, THCV significantly decreased fasting plasma glucose and…
RT @drmikehart: In a double-blind, randomized controlled trial in type 2 diabetics, THCV significantly decreased fasting plasma glucose and…
RT @drmikehart: In a double-blind, randomized controlled trial in type 2 diabetics, THCV significantly decreased fasting plasma glucose and…
RT @drmikehart: In a double-blind, randomized controlled trial in type 2 diabetics, THCV significantly decreased fasting plasma glucose and…
https://t.co/dAzJ56htVs
In a double-blind, randomized controlled trial in type 2 diabetics, THCV significantly decreased fasting plasma glucose and improved pancreatic β-cell function and apolipoprotein A (a marker for CVD disease) compared to placebo. https://t.co/2GXdYZjvXM https://t.co/f4rXSabuYO https://t.co/BpAhe54pwR
It is market & government failure that preparations of Tetrahydrocannabivarin (THCV) dominant cannabis are not available 6 years after medical ‘legalisation’ in Australia https://t.co/nW8Q75phBg
#THCV is good for your pancreas. https://t.co/TGMe5f95Ij
RT @trikomes: THCV is one of the most interesting minor cannabinoids associated with #cannabis. One thing I find particularly interesting…
THCV is one of the most interesting minor cannabinoids associated with #cannabis. One thing I find particularly interesting is that there's evidence it can cause physiological effects (e.g. lower plasma glucose) when consumed at a low dose (5-10 mg). https://t.co/tZcGANLYLI
TRPV1 eh . https://t.co/QQMU4VMDh5 https://t.co/5al1471SZL https://t.co/nW8Q75phBg
@Greenthumb_one @ParabolaCenter @vsaffron https://t.co/BuT55aLJ7n
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study https://t.co/1nuPHtYVel https://t.co/zxARqj0CgE
RT @Kevin_McKernan: COVID is an opportunistic accelerant of metabolic disease. ~90% of patients are comorbid with diabetes, hypertension, c…
RT @Kevin_McKernan: COVID is an opportunistic accelerant of metabolic disease. ~90% of patients are comorbid with diabetes, hypertension, c…
RT @Kevin_McKernan: COVID is an opportunistic accelerant of metabolic disease. ~90% of patients are comorbid with diabetes, hypertension, c…
RT @Kevin_McKernan: COVID is an opportunistic accelerant of metabolic disease. ~90% of patients are comorbid with diabetes, hypertension, c…
RT @Kevin_McKernan: COVID is an opportunistic accelerant of metabolic disease. ~90% of patients are comorbid with diabetes, hypertension, c…
RT @Kevin_McKernan: COVID is an opportunistic accelerant of metabolic disease. ~90% of patients are comorbid with diabetes, hypertension, c…
RT @Kevin_McKernan: COVID is an opportunistic accelerant of metabolic disease. ~90% of patients are comorbid with diabetes, hypertension, c…
RT @Kevin_McKernan: COVID is an opportunistic accelerant of metabolic disease. ~90% of patients are comorbid with diabetes, hypertension, c…
RT @Kevin_McKernan: COVID is an opportunistic accelerant of metabolic disease. ~90% of patients are comorbid with diabetes, hypertension, c…
RT @Kevin_McKernan: COVID is an opportunistic accelerant of metabolic disease. ~90% of patients are comorbid with diabetes, hypertension, c…
RT @Kevin_McKernan: COVID is an opportunistic accelerant of metabolic disease. ~90% of patients are comorbid with diabetes, hypertension, c…
RT @Kevin_McKernan: COVID is an opportunistic accelerant of metabolic disease. ~90% of patients are comorbid with diabetes, hypertension, c…
RT @Kevin_McKernan: COVID is an opportunistic accelerant of metabolic disease. ~90% of patients are comorbid with diabetes, hypertension, c…
COVID is an opportunistic accelerant of metabolic disease. ~90% of patients are comorbid with diabetes, hypertension, cancer, COPD. Cannabinoids are metabolic regulators. RCT on CBD and THCV for TypeII diabetes. https://t.co/CItWUU0GMG
@Greenthumb_one @fundacioncanna https://t.co/imleSqTS7v.... I think still the only RCT in this area??
https://t.co/ZKkNIxp5YU #ヘンプ論文
https://t.co/ZKkNIxGGQs #ヘンプ論文
。 https://t.co/Res8RF2DES https://t.co/ZKkNIxGGQs #ヘンプ論文
カンナビジオールおよびTetrahydrocannabivarinの効率性と安全性は、2型糖尿病による患者のグリセムとリピッドパラメータで、ランダム化、二重ブラインド、Placebo- Controlled、パラレル・グループ・パイロット・スタディーという https://t.co/ZKkNIxGGQs #ヘンプ論文
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study https://t.co/7XSuWeLtxI https://t.co/btIjZQRPbE
RT @wearedaco: Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabe…
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes- A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.pdf - Google Drive https://t.co/MkGWuVZvHL